HOME >> BIOLOGY >> NEWS
Cyclacel's biomarker technology shows that CYC202 induces cancer cells to commit suicide

Washington, DC, 14 July 2003 - Cyclacel Limited, the UK-based biopharmaceutical company, reported today that it demonstrated through state-of-the-art biomarker technology that CYC202 (R-roscovitine), its lead CDK inhibitor drug candidate, appears to induce cancer cell suicide or apoptosis in patients receiving the drug. Details of the biomarker data obtained with CYC202 were reported today at an oral presentation at the American Association for Cancer Research (AACR) annual meeting taking place here.

Biomarker technology is used to understand the molecular mechanism of action of novel drugs in humans, provide insights into their pharmacological properties, measure their biological effect (e.g. induce cancer cells to commit suicide) and determine susceptibility or resistance to the treatment. In the long-term biomarker analysis of tumour blood and tissues may allow selective treatment with CYC202 of those patients identified as likely to benefit from the drug based on the specific genetic profile of their tumour.

Biomarker analysis of blood samples from patients with cancer treated with CYC202 demonstrated that 54% (14 of 26 analysed) tested positive for cancer cell death or apoptosis following single agent treatment with the drug. In addition, seven CYC202 Phase I patients with various tumours, including pancreas and lung cancer, experienced long lasting tumour stabilisation. These patients received CYC202 capsules taken by mouth after exhausting other treatment options. CYC202 is presently being tested in two international, multicentre Phase IIa clinical trials for the treatment of breast and lung cancer in combination with standard chemotherapy.

Cyclacel's Biomarker Team used a novel assay technique to calculate the extent by which cancer cells are committing suicide (or apoptotic index) in different patients on the drug. An advantage of this test is that it measures cellular material released into the circulation by dying or dead cance
'"/>

Contact: Robert Gottlieb
robert.gottlieb@fkhealth.com
617-577-8110
Feinstein Kean Healthcare
14-Jul-2003


Page: 1 2 3

Related biology news :

1. New drug target and biomarker for advanced childhood cancer discovered
2. Protein biomarkers accurately and quickly diagnose ALS, find Pittsburgh researchers
3. Ki-67 biomarker a strong predictor of outcome for prostate cancer patients
4. Illinois study seeking biomarkers of canine diabetes, other diseases
5. Oral contraceptives increase C-reactive protein, an infIammatory biomarker
6. Promising biomarker for melanoma is identified
7. UC Davis M.I.N.D. Institute launches new program to identify biomarkers for autism and other disorders
8. Yale digital diagnostic technology is basis of new company, HistoRx Inc.
9. AACR applauds NCI initiative on nanotechnology
10. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
11. New imaging technology at Joslin shown to detect early signs of type 1 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/4/2019)... , ... October 04, 2019 , ... ... will be held November 10 at the Grand Elysée Hamburg Rothenbaumchaussee in Hamburg. ... Europe again this November,” said Miao Guo, Vice President of Operations and spokesperson ...
(Date:10/3/2019)... ... October 02, 2019 , ... ... financing and ongoing support for Connecticut’s innovative, growing companies, today announced that it ... for mobile payments and winner of the 2018 VentureClash competition. ...
(Date:9/30/2019)... , ... September 30, 2019 ... ... disrupter and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing ... product formulations related to “Ready-to-Print” (RTP) cellular product formats (patent number AU ...
Breaking Biology News(10 mins):
(Date:10/15/2019)... , ... October 14, 2019 , ... ARPR , an award-winning tech PR agency ... honored as a Health Care Agency of the Year in the Ragan’s Health Care ... as a finalist by Ragan’s. The firm also revealed today that its healthIT practice group ...
(Date:10/10/2019)... ROCKVILLE, Md. (PRWEB) , ... October 09, 2019 ... ... Thursday, October 10th, groups of Montgomery County middle school and high school students ... to handle stressors, utilize relaxation techniques and physical fitness, and apply lifelong social/interpersonal, ...
(Date:10/10/2019)... ... October 10, 2019 , ... ... largest network of clinical research centers in Europe. All Pratia research centers have ... Europe to become trained and certified as Virtual Trial Capable and prepared to ...
(Date:10/8/2019)... ... October 07, 2019 , ... Erchonia Corporation, ... technology (“3LT®”), today announces that the U.S. Food and Drug Administration (FDA) has ... for the temporary relief of chronic neck and shoulder pain of musculoskeletal origin. ...
Breaking Biology Technology:
Cached News: